Aeolus Pharmaceuticals (Aeolus Pharmaceuticals) FCF Margin % : -4,446.15% (As of Jun. 2017)

View and export this data going back to 1996. Start your Free Trial

What is Aeolus Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aeolus Pharmaceuticals's Free Cash Flow for the three months ended in Jun. 2017 was $-0.58 Mil. Aeolus Pharmaceuticals's Revenue for the three months ended in Jun. 2017 was $0.01 Mil. Therefore, Aeolus Pharmaceuticals's FCF Margin % for the quarter that ended in Jun. 2017 was -4,446.15%.

As of today, Aeolus Pharmaceuticals's current FCF Yield % is 0.00%.

The historical rank and industry rank for Aeolus Pharmaceuticals's FCF Margin % or its related term are showing as below:

AOLS' s FCF Margin % Range Over the Past 10 Years
Min: -434.89 Med: 0 Max: 0
Current: -434.89

AOLS's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs AOLS: -434.89

Aeolus Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Aeolus Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aeolus Pharmaceuticals FCF Margin % Chart

Aeolus Pharmaceuticals Annual Data

Trend

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

Sep15

Sep16

FCF Margin %

Get a 7-Day Free Trial

-12.05

-75.61

3.35

-78.53

-149.76

Aeolus Pharmaceuticals Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
FCF Margin %	Get a 7-Day Free Trial															-114.09	-110.07	-1,518.07	-708.53	-4,446.15

Competitive Comparison of Aeolus Pharmaceuticals's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aeolus Pharmaceuticals's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's FCF Margin % falls into.

Aeolus Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aeolus Pharmaceuticals's FCF Margin for the fiscal year that ended in Sep. 2016 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2016 )	/	Revenue (A: Sep. 2016 )
	=	-3.109	/	2.076
	=	-149.76 %

Aeolus Pharmaceuticals's FCF Margin for the quarter that ended in Jun. 2017 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2017 )	/	Revenue (Q: Jun. 2017 )
	=	-0.578	/	0.013
	=	-4,446.15 %

Aeolus Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aeolus Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aeolus Pharmaceuticals (Aeolus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aeolus Pharmaceuticals Inc (OTCPK:AOLS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691

Website

http://www.aolsrx.com

Aeolus Pharmaceuticals Inc is a Southern California based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.

Executives

John L Mcmanus	officer: President and CEO	C/O AEOLUS PHARMACEUTICALS, INC., 26361 CROWN VALLEY PARKWAY, SUITE 150, MISSION VIEJO CA 92691
Chris A Rallis	director	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Amit Kumar	director	C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Joseph J Krivulka	director	C/O DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
David Cavalier	director	C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Michael E Lewis	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Peter David Suzdak	director	1204 MEADOWLARK DRIVE, TOWSON MD 21286
Russell Skibsted	officer: Chief Financial Officer	15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Mark Lappe	10 percent owner	11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Bvf Investments Llc	10 percent owner, other: Indirect Beneficial Owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	10 percent owner, other: Indirect Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner, other: Indirect Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner, other: Indirect Beneficial Owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P	10 percent owner, other: Indirect Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jon Faiz Kayyem	10 percent owner	5964 LA PLACE COURT, CARLSBAD CA 92008

Aeolus Pharmaceuticals (Aeolus Pharmaceuticals) Headlines

From GuruFocus

Aeolus Announces Commencement of Assignment for the Benefit of Creditors

By ACCESSWIRE AccessWire • 04-12-2019